Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Paraquat Parkinson’s Disease Lawsuits Exposure to the toxic herbicide Paraquat has been linked to a risk of Parkinson's disease.
Gardasil HPV Vaccine Lawsuit Side effects of the Gardasil HPV vaccine have been linked to reports of serious and debilitating autoimmune injuries. Lawyers review cases nationwide.
Actos Litigation Status Conference Set for Tomorrow in MDL August 20, 2014 Austin Kirk Add Your Comments Attorneys involved in the federal Actos bladder cancer lawsuits are scheduled to meet tomorrow with the U.S. District Judge presiding over the consolidated litigation, providing an update on the status of thousands of cases pending against Takeda Pharmaceuticals. There are currently more than 3,600 product liability lawsuits pending before U.S. District Judge Rebecca Doherty in the Western District of Louisiana, which all involve similar claims that plaintiffs developed bladder cancer from side effects of Actos. Takeda Pharmaceuticals has been accused of withholding information about the potential risk associated with the diabetes drug from consumers and the medical community. Learn More About Actos Lawsuit Side effects of Actos may increase the risk of bladder cancer. Lawsuits are pending nationwide. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Actos Lawsuit Side effects of Actos may increase the risk of bladder cancer. Lawsuits are pending nationwide. Learn More SEE IF YOU QUALIFY FOR COMPENSATION In the federal court system, the Actos cases have been centralized as part of a Multidistrict Litigation (MDL) before Judge Doherty to reduce duplicative discovery into common issues in the lawsuits, avoid conflicting pretrial rulings issued by different judges and to serve the convenience of witnesses, parties and the courts. Judge Doherty issued an agenda (PDF) this week for a status conference scheduled for August 21, at which time lawyers representing plaintiffs in the litigation and attorneys for Takeda Pharmaceuticals are expected to update the Court on recent developments in the Actos litigation, provide information on the number of new cases filed in state and federal courts nationwide, as well as an update on progress with discovery and other pretrial proceedings. Actos Bellwether Trials The status conference comes in the wake of a $9 billion verdict in the first Actos bellwether trial held in the federal MDL earlier this year. The case was scheduled as the first in a series of trials designed to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation. While the outcomes of these early trial dates are not binding in other cases, they are designed to promote possible Actos settlement agreements that may avoid the need for thousands of individual trials to be scheduled nationwide. Following the record setting verdict, Takeda Pharmaceuticals has filed motion to overturn or reduce the award, which included $1.5 million in compensatory damages and $9 billion in punitive damages designed to punish the drug makers for withholding information about the link between Actos and bladder cancer. In addition to cases pending before Judge Doherty in the federal Actos MDL, a large number of cases have been filed in various state courts throughout the country. At least four trials have already taken place at the state level, with conflicting results. In May 2013, a California jury awarded $6.5 million in damages over Actos bladder cancer in a case brought by Jack Cooper, who was given an expedited trial date due to his grave health. However, following post-trial motions, that verdict was reversed after the state court judge excluded the plaintiffs’ expert witness testimony. A second trial was held in Maryland state court in September 2013, which resulted in a jury finding that Takeda failed to adequately warn about the risk of bladder cancer from Actos and awarding $1.77 million in damages. However, the case resulted in a defense verdict for the drug maker under a unique Maryland law, known as contributory negligence, as the jury also found that the plaintiff failed to exercise reasonable care for his own health, which nullified the negligence of the drug maker. A third Actos bladder cancer trial concluded late last year in Nevada state court, which resulted in a defense verdict after the jury determined that both Actos and the plaintiff’s history as a smoker contributed to the development of bladder cancer. In that case, the plaintiff also ordered generic versions of Actos from online pharmacies, which raised questions as to whether Actos or unknown factors in the generic versions purchased online could have contributed to the development of the disease in that case. Only weeks after the $9 billion verdict returned by a federal jury, another Actos trial in Las Vegas ended in a defense verdict. However, plaintiffs attorneys in that case are seeking a new trial because of the conduct of Takeda attorneys in front of the jury. During the trial, the Judge presiding over the case admonished the drug makers’ attorneys and advised the jurors that certain actions during the trial were inappropriate and should be disregarded. Additional state court trials are expected to begin in the fall. A second MDL bellwether trial was originally set to begin in April 2014, but that trial date was continued earlier this year. Tags: Actos, Bladder Cancer, Diabetes, Diabetes Drug, Takeda Pharmaceuticals More Actos Lawsuit Stories Actos Bladder Cancer Warnings Updated by FDA to Add New Study Data Reviewed December 13, 2016 Bladder Cancer Risk with Actos Highlighted in a New Study April 5, 2016 Actos Side Effects May Increase Risk of Bone Fractures, Weight Gain: Study March 1, 2016 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (Posted: 2 days ago) Parties involved in Covidien hernia mesh lawsuits indicate they are ready to meet with a mediator in a couple weeks to begin potential settlement negotiations. MORE ABOUT: HERNIA MESH LAWSUITCovidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025)Discovery Deadlines in Covidien Hernia Mesh Lawsuits Extended by MDL Judge (12/12/2024)Court Appoints Bard Hernia Mesh Settlement Special Masters To Implement “Intensive” Process To Resolve Claims (11/22/2024) Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (Posted: 3 days ago) A federal judge has outlined the schedule for preparing a group of hair relaxer lawsuits for early bellwether trials, which will not go before a jury until at least 2027. MORE ABOUT: HAIR RELAXER LAWSUITSynthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)Hair Relaxer Wrongful Death Lawsuit Links Fatal Endometrial Cancer to Chemical Straightener Use (03/04/2025)Hair Relaxer Lawsuit Settlement Talks Begin With Focus on Finding Mediator, Parties Report (02/11/2025) Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (Posted: 4 days ago) A BioZorb tissue marker lawsuit representing five women from across the country claims that the recalled implant was defectively designed, resulting in a recall and numerous complications. MORE ABOUT: BIOZORB LAWSUITBioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025)Judge Indicates BioZorb Recall and Warning Letter Do Not Warrant Reopening Discovery in Bellwether Cases (02/12/2025)
Mediation To Discuss Settling Covidien Hernia Mesh Lawsuits Set for March 31 Through April 4 (Posted: 2 days ago) Parties involved in Covidien hernia mesh lawsuits indicate they are ready to meet with a mediator in a couple weeks to begin potential settlement negotiations. MORE ABOUT: HERNIA MESH LAWSUITCovidien Hernia Mesh Settlement Talks To Get Underway After Parties Select Mediator Next Week (02/19/2025)Discovery Deadlines in Covidien Hernia Mesh Lawsuits Extended by MDL Judge (12/12/2024)Court Appoints Bard Hernia Mesh Settlement Special Masters To Implement “Intensive” Process To Resolve Claims (11/22/2024)
Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (Posted: 3 days ago) A federal judge has outlined the schedule for preparing a group of hair relaxer lawsuits for early bellwether trials, which will not go before a jury until at least 2027. MORE ABOUT: HAIR RELAXER LAWSUITSynthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)Hair Relaxer Wrongful Death Lawsuit Links Fatal Endometrial Cancer to Chemical Straightener Use (03/04/2025)Hair Relaxer Lawsuit Settlement Talks Begin With Focus on Finding Mediator, Parties Report (02/11/2025)
Breast Cancer Survivors File Lawsuit Over Recalled BioZorb Tissue Marker (Posted: 4 days ago) A BioZorb tissue marker lawsuit representing five women from across the country claims that the recalled implant was defectively designed, resulting in a recall and numerous complications. MORE ABOUT: BIOZORB LAWSUITBioZorb Attorneys Propose Leadership Structure for Lawsuits Over Recalled Tissue Marker (03/05/2025)Schedule Leading to First BioZorb Lawsuit Jury Trial in September 2025 Outlined By Court (02/21/2025)Judge Indicates BioZorb Recall and Warning Letter Do Not Warrant Reopening Discovery in Bellwether Cases (02/12/2025)